CONSTELLATION PHARMACEUTICALS PROVIDES UPDATE ON MANIFEST CLINICAL TRIAL OF CPI-0610 IN MYELOFIBROSIS

  • MPNRF | April 7, 2021

    Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs

    • Constellation CEO Jigar Raythatha will present at the J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019, at 4PM PST/7PM EST
    • The presentation will include updated results from the first four patients in the MANIFEST Phase 2 clinical trial, demonstrating potentially disease-modifying effects of CPI-0610 and its potentially differentiated safety profile vs. other BET inhibitors
    • Presentations of interim clinical data from the MANIFEST Phase 2 clinical trial of CPI-0610 and the Phase 1b portion of the ProSTAR clinical trial of CPI-1205 in prostate cancer are planned for medical meetings in the second quarter of 2019
    • Constellation plans to initiate a Phase 1 clinical trial of CPI-0209 in mid-2019

    CLICK HERE TO LEARN MORE